Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement

This two-step strategy could set investors up with a large sum of passive income in retirement.

MSFT : 438.69 (+1.83%)
GOOGL : 162.14 (+1.46%)
AAPL : 228.87 (+3.71%)
AMZN : 189.87 (+1.85%)
NVDA : 117.87 (+3.97%)
AVGO : 167.42 (+3.56%)
GOOG : 163.24 (+1.51%)
JPM : 210.48 (+1.42%)
XOM : 116.00 (+1.24%)
JNJ : 164.82 (-0.80%)
PG : 171.54 (-1.37%)
$SPX : 5,713.64 (+1.70%)
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?

Shares of Intuitive Surgical ISRG have risen 14.2% in the past three months, outperforming the Zacks Medical - Instruments industry’s growth of 3.8% and the broader Zacks Medical sector’s return of...

JNJ : 164.82 (-0.80%)
MDT : 89.47 (+1.52%)
ISRG : 490.01 (+1.64%)
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for the industry. The stock has also outperformed the sector and the S&P 500, as...

SNY : 58.26 (+1.37%)
JNJ : 164.82 (-0.80%)
TEVA : 17.76 (-0.67%)
ABBV : 193.62 (+0.35%)
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative colitis. Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight...

REGN : 1,150.19 (+1.00%)
SNY : 58.26 (+1.37%)
JNJ : 164.82 (-0.80%)
NVO : 134.88 (+2.14%)
Should You Buy Novavax Stock After This Regulatory Win?

The biotech continues to earn important wins, but is it enough?

MRNA : 68.02 (-2.63%)
BNTX : 112.51 (-2.69%)
JNJ : 164.82 (-0.80%)
PFE : 29.66 (-0.30%)
NVAX : 12.52 (-0.32%)
SNY : 58.26 (+1.37%)
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third indication. The drug is approved to treat adults with moderately to severely...

JNJ : 164.82 (-0.80%)
LLY : 915.04 (+1.11%)
ABBV : 193.62 (+0.35%)
Is Hims & Hers Health the Next Teladoc?

Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.

PFE : 29.66 (-0.30%)
JNJ : 164.82 (-0.80%)
TGT : 156.49 (+1.88%)
NVO : 134.88 (+2.14%)
LLY : 915.04 (+1.11%)
TDOC : 9.18 (+0.99%)
MRNA : 68.02 (-2.63%)
HIMS : 16.92 (+3.74%)
2 Stocks That Are Passive Income Machines to Buy and Hold Forever

You can take these dividends straight to the bank.

ABT : 114.15 (-0.64%)
JNJ : 164.82 (-0.80%)
Is Johnson & Johnson Underperforming the S&P 500?

Johnson & Johnson has underperformed the S&P 500 recently, but analysts are moderately optimistic about the stock’s potential.

JNJ : 164.82 (-0.80%)
$SPX : 5,713.64 (+1.70%)
LLY : 915.04 (+1.11%)
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem

Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.

INTC : 21.14 (+1.78%)
WBA : 8.98 (-0.33%)
JNJ : 164.82 (-0.80%)
MO : 50.23 (-0.79%)

Barchart Exclusives

How Surging AI Demand Could Drive This Dividend Stock Higher
Eaton, a diversified power management company, is poised to benefit from the surging demand for AI-driven data centers, with its innovative power solutions and strong dividend growth making it an attractive investment opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar